Japan’s Ministry of Health, Labor and Welfare (MHLW) has issued new guidance on how the country’s conditional approval system for pharmaceuticals will be operated under the revised Pharmaceuticals and Medical Devices (PMD) Act, which takes effect in May. In a…
To read the full story
Related Article
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- MHLW Issues 15 Notices Ahead of PMD Act Amendment
March 2, 2026
REGULATORY
- MFN Now a Factor in Japan’s Drug Pricing Debate: New Pharma Policy Chief
September 11, 2026
- MHLW to Weigh Survey Data, Past Approach for FY2027 Revision: Official
September 10, 2026
- Chuikyo Reps Back Greater Transparency, but Lean toward Broader CEA Price Cuts
September 10, 2026
- OTC-Like Drug Charge Gets Prescription Field; No Double Charge with LLP Rule
September 10, 2026
- Defense Chief Seeks MHLW Help Securing Drugs for SDF
September 9, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





